Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic
Ribon, backed by biopharma majors, raises $65M to take PARP7 [...]
Eli Lilly’s $1B buyout bet for Protomer brings the ‘next frontier’ in smart insulin tech under the Big Pharma’s wing
Eli Lilly’s $1B buyout bet for Protomer brings the ‘next [...]
Ionis pays Bicycle $45M to expand oligonucleotide delivery toolkit
Ionis pays Bicycle $45M to expand oligonucleotide delivery toolkit ntaylor [...]
Nimbus raises $105M for multifront TYK2 clinical trial program
Nimbus raises $105M for multifront TYK2 clinical trial program ntaylor [...]
Biogen taps Chinese biotech InnoCare in $125M midstage MS drug pact
Biogen taps Chinese biotech InnoCare in $125M midstage MS drug [...]
Penn team uses CRISPR to edit out genetic disease before and after birth in mice
Penn team uses CRISPR to edit out genetic disease before [...]
Poxel pivots to different programs, but questions abound over imeglimin
Poxel pivots to different programs, but questions abound over imeglimin [...]
Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion
Novo Nordisk puts $1.2B on the table for Prothena’s ATTR [...]
FDA puts Sigilon’s hemophilia cell therapy trial on hold thanks to safety concerns
FDA puts Sigilon’s hemophilia cell therapy trial on hold thanks [...]
J&J, Vor ally to assess bispecific and stem cell therapy in AML
J&J, Vor ally to assess bispecific and stem cell therapy [...]